reported the significant therapeutic benefits of combining a PD-1 antibody, an HDACi, and a VEGF antibody in treating patients with microsatellite stable/proficient mismatch repair advanced colorectal cancer (59). This evidence concerns the gene VEGFA and colorectal cancer.